MiR-205 (or Triacsin C, an inhibitor of ACSL4) suppressed HBx’s ability to raise cellular cholesterol levels (a metabolite of ACSL4) in hepatoma cells. Here, ACSL4 is linked to hepatocellular carcinoma.